Share
News
-
23 December 2008 /Retail and online sale
Campaign: Avoiding dangerous erectile dysfunction drugs on the internet
It's very easy to find and buy anti-impotence pills on the internet. Unfortunately, many of them are not approved by the authorities. This means that they may be extremely harmful.
-
22 December 2008 /Side effects and trials
From New Year the Danish Medicines Agency will take over the contact to doctors who report adverse reactions
In the new year, the contact between doctors reporting adverse reactions and the pharmaceutical companies responsible will take place via the Danish Medicines Agency.
-
19 December 2008 /Prices and reimbursement
Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)
The Danish Medicines Agency's assessment of the future reimbursement status of the dihydropyridine calcium antagonists (C08CA) were submitted for consultation with 11 November 2008 as the consultation deadline.
-
10 December 2008 /Side effects and trials
Conventional antipsychotics may cause increased risk of death in elderly people with dementia
It is known that the so-called atypical antipsychotic agents are assoctiated with an increased risk of death in elderly people with dementia.
-
27 November 2008 /Prices and reimbursement
Reassessment of reimbursement status for 5 combination products in ATC groups C07, C08 and C09
The Danish Medicines Agency has assessed the question of the future reimbursement status for five combination products in ATC groups C07, C08 and C09 on the basis of updated information about prices and consumption of these medicinal products.
-
21 November 2008 /Prices and reimbursement
Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases
The Reimbursement Committee’s additional recommendation concerning the future reimbursement status of medicinal products for cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensives) was submitted for consultation with 19 September 2008 as the consultation deadline
-
20 November 2008 /Authorisation and supervision
Control of Eprex®
The Danish Medicines Agency has determined the activity of seven different batches of Eprex®. Eprex® is used for the treatment of anaemia in case of chronic renal failure.
-
20 November 2008 /Side effects and trials
New information about cardiovascular adverse reactions from the use of NSAID
A Danish study has provided information about the cardiovascular safety of using pain-killing medicinal products of the NSAID type. The study is a well-designed pharmacoepidemiological study based on, among other things, information from the Danish Register of Medicinal Product Statistics, and it was published on 5 November 2008 at the website of the journal Clinical Pharmacology & Therapeutics.
-
10 November 2008 /Authorisation and supervision
Sale or delivery of advanced therapy medicinal products on 30 December 2008
The regulation on advanced therapy medicinal products (Regulation (EC) no. 1394/2007 of 13 November 2007), which enters into force on 30 December 2008, contains a transitional provision for medicinal products sold or delivered legally in the EU on this date.
-
10 November 2008 /Authorisation and supervision
Control of medicinal product labelling (fall 2008)
The Danish Medicines Agency has controlled different elements of the labelling in the below medicinal products, due to, among other things, complaints and reports submitted to the Danish Patient Safety Database.
-
10 November 2008 /About us
Digitisation of the Danish Medicines Agency
On 30 October 2008, the Danish Finance Committee approved the Danish Medicines Agency's contract with IBM about the digitisation programme DAHLIA.
-
31 October 2008 /Authorisation and supervision
Control of streptokinase-containing medicinal products
The Danish Medicines Agency's laboratory has tested five different products that contain the active substance streptokinase, which is used for the treatment of blood clots.
-
31 October 2008 /Authorisation and supervision
Control of oral suspensions
The Danish Medicines Agency's laboratory has analysed six different oral suspensions. The control was carried out in response to a complaint about microbiological contamination in one of the products after opening.
-
29 October 2008 /Prices and reimbursement
Reassessment of reimbursement status for medicinal products in ATC group C08CA
The Danish Medicines Agency has assessed the question of the future reimbursement status for medicinal products in ATC group C08CA (dihydropyridine calcium channel blockers) which are used for the treatment of cardiovascular diseases.
-
27 October 2008 /Side effects and trials
Second place isn’t good enough – the Danish Medicines Agency increases its focus on the reporting of adverse drug reactions
Among the European countries, Denmark is only surpassed by France when it comes to gathering the proportionately largest number of reports on side effects from medicine.
-
27 October 2008 /Side effects and trials
EMEA recommends to suspend the licence for the weight-loss product Acomplia® across the EU
The European Medicines Agency (EMEA) has recommended that the licence for Acomplia® from the company Sanofi-Aventis be suspended across the EU. The EMEA's Committee for Medicinal Products for Human Use (CHMP) has assessed that the benefits of the rimonabant-containing Acomplia® no longer outweigh its risks.
-
21 October 2008 /News - miscellaneous
Warning against scare campaign
"EU will ban natural vitamins" and "In the future, you can only buy your vitamins at the pharmacy". These are but two of the scare messages contained in Danish chain mails that thousands of Danes have been receiving over the past few weeks.
-
10 October 2008 /News - miscellaneous
Illegal distribution of electronic cigarettes
Recently, the Danish Medicines Agency has been made aware that a number of electronic cigarettes, and similar products, are being sold illegally, e.g. via the internet. The products are sold under various product names.
-
07 October 2008 /Prices and reimbursement
Executive order on calculation of consumer prices, etc. of medicinal products
On 6 October 2008, a new executive order on price calculation enters into force, repealing executive order no. 270 of 21 March 2007 with the same title.
-
30 August 2007 | Updated 06 October 2008 /Side effects and trials
Consumption and adverse reactions to treatment of attention and hyperactivity disorders in children
The consumption of medicinal products for treatment of ADHD (Attention Deficit/Hyperactivity Disorder) in children has increased significantly over the past years.
